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BRCT domains are versatile protein modular domains found as single units or as multiple copies in
more than 20 different proteins in the human genome. Interestingly, most BRCT-containing
proteins function in the same biological process, the DNA damage response network, but show spec-
iﬁcity in their molecular interactions. BRCT domains have been found to bind a wide array of ligands
from proteins, phosphorylated linear motifs, and DNA. Here we discuss the biology of BRCT domains
and how a domain-centric analysis can aid in the understanding of signal transduction events in the
DNA damage response network.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The modular nature of the DNA damage response
When damage to DNA is detected a number of signaling events
are initiated at the site of damage in the chromatin and radiate to
other subcellular compartments. These signaling events perform
several functions including the tagging of damage sites, the hierar-
chical recruitment of proteins required for repair of the lesion, and
the temporal coordination of repair processes with progression of
the cell cycle [1]. They are part of the DNA damage response
(DDR) network and several of its main components have been
uncovered in the last 15 years [2,3]. Because several excellent
reviews have been published on the subject [1–8] here we will
focus on one speciﬁc topic: the modular nature of the DDR
network.
The identiﬁcation and characterization of DDR upstream
kinases ATM, ATR, and DNA-PK and several of their substrates
revealed an extensive signaling network in which phosphorylation
played a major role [8–10]. In addition, several protein phospha-
tases have also been implicated in the DDR [11,12]. Analysis ofchemical Societies. Published by E
DDR, DNA damage response;
ne; pThr, phosphothreonine;
f; PDB, Protein Data Bank
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pt.target sequences for the DDR kinases and phosphatases reveals a
preponderance of phosphorylation events on serine and threonine
residues rather than phosphorylation on tyrosine residues as is
commonly found in several canonical growth factor receptor sig-
naling pathways [13–15].
Together with protein kinases and phosphatases, protein mod-
ular domains and short linear motifs (SLiMs) make up the DDR sig-
naling toolkit. Protein modular domains are protein regions that
can fold independently [16]. Many modular domains have been
implicated in mediating interactions with ligand proteins via short
(8–10 amino acids) linear motifs located in loops or disordered re-
gions [17]. Inspection of the known components of the DDR reveals
the prevalence of two modular domains in addition to 14-3-3 pro-
teins: BRCT (BRCA1 C-terminal domain) and FHA (Forkhead associ-
ated domain) domains [18,19].
BRCT (BRCA1 C-terminus; PFAM PF00533) domains, initially
identiﬁed in the breast and ovarian cancer susceptibility gene
product BRCA1, are protein–protein interaction modules found in
a wide array of prokaryotic and eukaryotic proteins ranging from
one up to eight units [20–24]. Germline mutations that disrupt
the BRCT domains of BRCA1 are associated with a signiﬁcantly in-
creased risk for breast and ovarian cancers [25–28]. The human
genome contains at least 23 genes coding for proteins with BRCT
domains and most are implicated in the DDR (Woods et al. unpub-
lished). BRCT domains are found in all three superkingdoms,
Archaea, Eubacteria, and Eukarya, which supports the notion that
they have an early origin [20,29].lsevier B.V. All rights reserved.
2712 D.L. Gerloff et al. / FEBS Letters 586 (2012) 2711–2716The FHA domain (PFAM PF00498) is formed by 65–100 amino
acid residues and was initially recognized in forkhead transcription
factors found in prokaryotic and eukaryotic proteins [30]. The FHA
domain was shown to be required for the development of the fruit-
ing body in the proteobacterium Myxococcus xanthus that under-
goes a multicellular stage [31]. Human proteins, such as CHK2,
RNF8, CHFR, NBS1, and MDC1, which contain FHA domains, have
well characterized roles in the DDR [32–38]. Notably, two key
DDR proteins NBS1 and MDC1 contain BRCT and FHA domains
[39,40].
At least a subset of BRCT and FHA domains have been shown to
bind SLiMs phosphorylated by DNA damage-activated kinases with
BRCTs showing a preference for phosphoserine (pSer) and the FHAs
preferring phosphothreonine (pThr) [41–49]. SLiM binding speci-
ﬁcity for characterized tandem BRCT and a subset of FHA domains
is determined by a bipartite recognition that involves two distinct
pockets: one that recognizes the phosphorylated Serine or Threo-
nine and another pocket that recognizes the +3 residue (pSer/pThr
is considered the zero position) and is thought to provide speciﬁc-
ity (Supplementary Table 1) [41,42,44,47–52]. The recognition and
binding of cognate phosphorylated motifs by proteins with BRCT or
FHA domains can lead to changes in protein function and location.BRCA1 LIG4
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Fig. 1. The localization space of BRCT domain-containing proteins. Gene Ontology term
domain containing proteins were extracted from the GOA database (http://www.ebi.ac.uk
membrane) were used to generalize the localization space overlap between the indicated
selected terms, right panel. (B) Assignment to each of the cellular component GO terms
McQuitty’s criteria for the linkage rule. Yellow indicates an assignment of the GO term,However, our knowledge about the speciﬁcity determinants for
these linear motifs is still incomplete (Supplementary data).
FHA domains have only been found present as isolated in-
stances but BRCT domains present a more diverse domain arrange-
ment: besides many occurrences of single and tandem BRCT
domains it is also found as a triplet in TOPBP1 [53,54]. It is also
important to note that instances of either FHA or BRCT domains
might also bind other proteins via more extensive surface interac-
tion or via other linear motifs that do not depend on phosphoryla-
tion or other post-translational modiﬁcations. This is the case for
structurally characterized examples of TP53BP1-TP53 and LIG4-
XRCC1 interactions [55,56]. Also, we have recently identiﬁed a
poly-lysine stretch that mediates the interaction between the BRCT
of LIG4 and PA2G4 [57]. Some FHA domains require extended sur-
face interactions such as the binding of the KI-67 FHA to hNIFK
phosphopeptide [58,59].
Besides the BRCT and FHA domains other modular domains
have also been shown to play critical roles in the DDR. The role
of tandem Tudor domains found in TP53BP1 is an example that
also illustrates a cooperative relationship with BRCT domains.
Tudor domains (PFAM PF00567) are formed by a strongly bent
anti-parallel b-sheet consisting of ﬁve b-strands with a barrel-liketBRCT Protein
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s describing the cellular component associated with each of the indicated BRCT
/GOA/). (A) Four predominant terms (chromosome, nucleus, cytoplasm, and plasma
tBRCT domain containing proteins, left panel, and their assignments to each of the
was used to cluster the BRCT domain containing proteins using PermutMatrix with
black indicates no association with the GO term.
D.L. Gerloff et al. / FEBS Letters 586 (2012) 2711–2716 2713fold [60]. While recognition of phosphorylated Ser139 in Histone
H2AX by the TP53BP1 BRCT domain is required for TP53BP1 reten-
tion at DNA damage sites, initial recruitment depends on the
recognition of methylated lysines, preferentially Histone H4 dime-
thylated on Lys20, by its Tudor domains [61–64].
From the analysis of speciﬁc protein–protein interactions we
can determine the mechanistic basis of signaling in the DDR. How-
ever, an operational understanding of DDR dynamics will require a
network level approach at a modular domain resolution (in which
regulatory domains, SLiMs, and enzymes that modify them are
well annotated). Here we focus on BRCT domains and how their
global analysis can help in our understanding of the DDR.
2. Commonality of fold and speciﬁcity of function (more than
kin, less than kind)
The organization of DDR signaling events in time and space de-
pends on a large number of protein–protein interactions, someBRCA1 BARD1
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Fig. 2. Backbone and surfaces of crystallized human tandem BRCT domains. (A) Back
Electrostatic potential (from red:7 kT/e to blue: +7 kT/e) mapped onto solvent-accessibl
Schrödinger, LLC) and APBS Tools2 (Lerner MG, Carlson HA (2006) APBS plugin for PyMOL
chain identiﬁers is provided in the text.constitutive and some inducible. A fascinating problem in signal
transduction is how a set of proteins with multiple overlapping
functions achieve speciﬁcity. An analysis of mitotic kinases and
protein complexes reveals that speciﬁcity can be achieved through
a combination of selection among kinase target motifs (motif
space) and distinct subcellular localization (localization space)
[65].
Using Gene Ontology (GO) [66] terms for subcellular compart-
ment we see that there is considerable overlap in the localization
of proteins with tandem BRCT proteins (Fig. 1A) (Supplementary
data). This suggests that selection of binding motifs might play a
critical role in deﬁning speciﬁcity as most of these BRCT-containing
proteins share the same subcellular compartment. Interestingly,
clustering all BRCT proteins according to the GO annotation shows
that BRCT proteins sharing structural and sequence similarities do
not necessarily cluster according to subcellular compartment
(Fig. 1B). This is perhaps not surprising considering that many
signals and motifs that control localization, such as nuclear locali-TP53BP1 MDC1
MCPH1TOPBP1
MCPH1TOPBP1
TP53BP1 MDC1
bone ribbon diagrams (colored from blue (N-terminus) to red (C-terminus). (B)
e surfaces. Graphics produced with PyMOL (Molecular Graphics System, Version 1.3,
. Ann Arbor, MI: University of Michigan). Information about PDB accession codes and
2714 D.L. Gerloff et al. / FEBS Letters 586 (2012) 2711–2716zation or nuclear export sequences, are located outside of BRCT do-
mains. Important caveats to this analysis are that GO terms may
not reﬂect most recent ﬁndings in the literature for several pro-
teins, and proteins that are better studied have more detailed local-
ization annotation than less studied ones (e.g. compare BRCA1 with
ANKRD32). In addition, while some proteins may overlap in their
general location (e.g. associated with chromosomes), their distribu-
tion may vary within that compartment (e.g. associated with DNA
lesion versus evenly distributed in chromatin).
Despite the caveats of these preliminary analyses, our incom-
plete knowledge of which motifs are recognized by BRCT domains,
and the precise localization of these proteins we can derive insights
about the speciﬁcity of modular domain interactions by turning our
attention to the structure of BRCT domains. Here we focus on eight
tandem BRCT domains in human proteins for which crystallograph-
ically-determined structures are available in the Protein Data Bank
[67]: BRCA1 (1Y98_A), TP53BP1 (1KZY_C), MDC1 (2AZM_A), BARD1
(2NTE_B), LIG4 (3II6_Y), PAXIP1 (3SQD_A), TOPBP1 (2XNH_A), and
MCPH1 (3SHV_A).
Known BRCT domains share a general topology (arrangement)
of secondary structure elements where four or sometimes ﬁve par-
allel b-strands in their core are sandwiched between a-helices or
loop segments, in a three layered fold. Visual inspection of the pro-
tein backbones of the tandem BRCTs reveals a striking similarity of
their three-dimensional module arrangement in six examples (the
maximum sequence identity between any two structures is 33%)
(Fig. 2A). In LIG4 and TOPBP1 we ﬁnd some unusual domainFig. 3. Identiﬁcation of sites in the tandem BRCT under purifying (negative)
selection. Solvent-accessible surface of a representative structure (of the C-terminal
human BRCA1 fragment) highlighting potentially negatively selected sites. Side-
chain atoms shown in black are of amino acids whose codons show signs of having
evolved under negative selection. They were computed with the Selecton server
[73] across the entire alignment (see text, and Supplementary data) based on a
taxonomy-based phylogenetic tree for orthologous groups (not shown). ‘‘Top’’ and
‘‘Bottom’’ views are by reference to the orientation used in Fig. 2, i.e. the phospho-
binding pocket is on the top. Note that the MCPH1 BRCTs were excluded from this
analysis because complete coding sequences from elephant and opossum could not
be extracted (most likely due to incompleteness of their draft genomes).arrangements (Fig. 2A). For a detailed discussion of structural as-
pects of BRCT function the reader is referred to Leung et al. [21].
Despite this similarity of fold, visual inspection of space-ﬁlling
models highlighting the electrostatic properties mapped on their
surfaces reveals great differences, and thus suggests potential for
very different binding properties outside the pSer/pThr pocket
(Fig. 2B). Obviously not all differences are at ligand binding sites
and reﬂect differing binding speciﬁcities. However, comparative
analyses of electrostatic surfaces can help discern neutral from
adaptive changes and point to differing speciﬁcities in this way
(for example in eF1A1 and eF1A2) [68–70].
BRCT domains can interact with protein ligands by recognition
of linear motifs or through surface interactions. Linear motif and
surface-based interactions could conceptually be further subdi-
vided into constitutive or inducible interactions, e.g. binding is
inﬂuenced by post translation modiﬁcations.
To be capable of ﬁner analyses, we produced a structure-based
sequence alignment of seven tandem BRCT fragments and included
their orthologs from six mammalian species: man, dog, cow,
mouse, elephant, and opossum (Supplementary data). The protein
aligned sequences were used to align the encoding DNA sequences
(data not shown). Using these codon-alignments we were able to
identify sites in the BRCTs that likely evolved under purifying
selection pressure during evolution, as inferred by synonymous co-
dons that are signiﬁcantly overrepresented compared to non-syn-
onymous codons (Fig. 3). Sites under negative selection for all
tandem BRCT domains seem to coincide with the phosphopeptide
binding pocket at the ‘‘top’’, although not exclusively. By compar-
ison, we note a paucity of negatively selected sites over the
remainder of the protein surface. Besides corroborating our current
understanding, of phosphopeptide binding as a main function in
these tandem BRCT domains, analyses like these provide new test-
able hypotheses regarding which amino acids play critical roles in
this type of interaction. In addition, these analyses may identify
other negatively selected sites that do not coincide with the phos-
pho-peptide binding that may be important for the regulation and
function of BRCT-containing proteins.3. Conclusion
The DNA damage response is a fundamental cellular process
and understanding of the events involved and their regulation will
not only illuminate an important aspect of the life of a cell but will
also be critical to understand disease states and to improve treat-
ment. Because the DDR has been proposed to constitute an early
barrier to tumorigenesis [71,72] and DNA damage is at the basis
of common chemotherapy and radiotherapy this information is
going to be particularly relevant in the ﬁght against cancer.
From the perspective of signal transduction we can understand
the DDR as an integrated system with kinases and phosphatases,
linear motifs, and modular domains. Importantly, events in the
DDR are coordinated by the use of modular domains including
the FHA and BRCT domains. In our brief analysis described here
we explored the commonalities and speciﬁcities of select tandem
BRCT domains and provide a glimpse of how exploring of the mod-
ular nature of the DDR can improve our understanding of the DDR.
We show that tandem BRCT domains display a remarkable similar-
ity of backbone arrangement but divergent surfaces, suggesting
how a structurally conserved module present in a number of pro-
teins that share subcellular compartments can achieve versatility
in speciﬁc interactions with other proteins.
BRCT domain-centered functionality has not been extensively
explored beyond analysis of structural/surface aspects and SLiM
binding capabilities, which provide consistent predictions but lack
contextual analysis of its role as a scaffolding module in the DDR.
D.L. Gerloff et al. / FEBS Letters 586 (2012) 2711–2716 2715BRCT-SLiM interactions utilize a minimal amount of BRCT solvent
accessible area, leaving signiﬁcant areas on the BRCT domains well
suited for additional protein interactions. Therefore, domain-cen-
tric protein interaction studies are required to gather a compre-
hensive understanding of BRCT function within the cell. Data sets
cataloging BRCT interacting proteins will provide a framework
for understanding the cellular processes in which BRCT domains
participate. Interestingly, our results suggest that this type of do-
main-centric approach can differentiate BRCT domains that exhibit
divergent interaction proﬁles within common cellular processes of
the cell cycle and DDR (Woods, et. al., unpublished results).
As an extension, studies that take into consideration the tempo-
ral control of interactions determined by cell cycle progression or
ionizing radiation are required to understand the inducible nature
of the interactions and the role of the BRCT domains in these com-
plex signaling pathways. Adequate depth in delineating these
BRCT-mediated pathways could allow the integration of genetic
proﬁling and modern therapeutics to optimize cancer treatments
and patient outcomes.
Our ability to model structures on a network will be instrumen-
tal to advancing our understanding. Although still a future goal,
such networks can also be contextualized (i.e. according to tissue
characteristics, tissue speciﬁc expression, stimuli, or temporal
series). Perhaps more exciting is the possibility to personalize
these networks by overlaying genetic information. Conceivably,
the impact of germline genetic variation on protein interactions
could be used to identify patients more likely to suffer from side
effects. Likewise the impact of somatic genetic changes on protein
interactions in a tumor could be used to predict response to
chemotherapy or targeted therapies. Although many hurdles still
remain to a seamless integration of all these data sources we are
now in a position to put them to good (scientiﬁc and clinical) use.
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